1-3 of 3
Wayne P. Rothbaum
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Free
Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 5936–5938.
https://doi.org/10.1182/blood-2022-159568
Published: 2022
Journal Articles

A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53 WT , Ph+ Chronic Myeloid Leukemia

Free
Jorge E. Cortes, Omer Hassan Jamy, Guillermo Ortí, Felipe Prosper, Sebastian Grosicki, Anne Uyei, Wayne P. Rothbaum, Franck E. Nicolini
Journal: Blood
Blood (2021) 138 (Supplement 1): 2562.
https://doi.org/10.1182/blood-2021-145218
Published: 2021
Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Free
Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek
Journal: Blood
Blood (2021) 138 (Supplement 1): 3581.
https://doi.org/10.1182/blood-2021-147543
Published: 2021